Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2015

Open Access 01-12-2015 | Study protocol

A five-year randomized parallel and blinded clinical trial of an extended specialized early intervention vs. regular care in the early phase of psychotic disorders: study protocol

Authors: Danyael Lutgens, Srividya Iyer, Ridha Joober, Thomas G Brown, Ross Norman, Eric Latimer, Norbert Schmitz, Amal Abdel Baki, Sherezad Abadi, Ashok Malla

Published in: BMC Psychiatry | Issue 1/2015

Login to get access

Abstract

Background

Specialized Early Intervention services (SEI) for first episode psychosis are shown to be effective for the treatment of positive and negative symptoms, medication adherence, rates of relapse, substance abuse disorders, functional outcome and quality of life at two-year treatment follow up. However, it is also reported that these benefits are not maintained when SEI is not sustained. The objective of this trial is to test the efficacy of a 3-year extension of a SEI service (following 2 years of SEI prior to randomization) for the maintenance and consolidation of therapeutic gains as compared to regular care in the community.

Methods

Following an initial 2 years of SEI, patients are randomized to receive either 3-years of continued SEI or regular care. SEI provided at three sites within the McGill network of SEI services, using a model of treatment comprised of: modified assertive case management; psycho education for families; multiple family intervention; cognitive behavioural therapy; and substance abuse treatment and monitoring. Blinded research assistants conduct ongoing evaluation of the outcome variables every three months. The primary outcome measure is remission status measured both as the proportion of patients in complete remission and the mean length of remission achieved following randomization during the additional three years of follow up. Based on preliminary data, it is determined that a total of 212 patients are needed to achieve adequate statistical power. Intent to treat with the last observation carried forward will be the primary method of statistical analysis.

Discussion

The “critical period” hypothesis posits that there is a five year window during which the effects of the nascent psychotic illness can be countered and the impact of the disorder on symptomatic and functional outcomes can be offset through active and sustained treatment. Providing SEI throughout this critical period may solidify the benefits of treatment such that gains may be more sustainable over time as compared to intervention delivered for a shorter period. Findings from this study will have implications for service provision in first episode psychosis.

Trial registration

ISRCTN11889976
Literature
1.
Organization WHO. The World health report: 2001: Mental health: new understanding, new hope. 2001
2.
Rössler W, Joachim Salize H, Van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15:399–409.CrossRefPubMed
3.
4.
Morgan V, McGrath J, Jablensky A, Badcock J, Waterreus A, Bush R, et al. Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychol Med. 2013;44:2163–76.CrossRefPubMed
5.
Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1575–86.CrossRefPubMed
6.
Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull. 2014;40:744–455.CrossRefPubMed
7.
Ösby U, Hammar N, Brandt L, Wicks S, Thinsz Z, Ekbom A, et al. Time trends in first admissions for schizophrenia and paranoid psychosis in Stockholm County. Sweden Schizophr Res. 2001;47:247–54.CrossRefPubMed
8.
Mueser KT, Bennett M, Kushner MG. Epidemiology of substance use disorders among persons with chronic mental illnesses. 1995
9.
Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64:19–28.CrossRefPubMed
10.
Goeree R, Farahati F, Burke N, Blackhouse G, O’Reilly D, Pyne J, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin. 2005;21:2017–28.CrossRefPubMed
11.
Malla A, Norman R, Schmitz N, Manchanda R, BÉChard-Evans L, Takhar J, et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med. 2006;36:649–58.CrossRefPubMed
12.
Albert N, Bertelsen M, Thorup A, Petersen L, Jeppesen P, Le Quack P, et al. Predictors of recovery from psychosis: Analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5 years. Schizophr Res. 2011;125:257–66.CrossRefPubMed
13.
Austin SF, Mors O, Secher RG, Hjorthøj CR, Albert N, Bertelsen M, et al. Predictors of recovery in first episode psychosis: The OPUS cohort at 10 year follow-up. Schizophr Res. 2013;150:163–8.CrossRefPubMed
14.
Birchwood M, Fiorillo A. The critical period for early intervention. Psychiatr Rehabil Skills. 2000;4:182–98.CrossRef
15.
Jeppesen P, Petersen L, Thorup A, Abel M-B, Øhlenschlaeger J, Christensen T, et al. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med. 2008;38:1157–66.CrossRefPubMed
16.
Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Gervin M, et al. Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. Br J Psychiatry. 2009;194:18–24.CrossRefPubMed
17.
18.
Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatr. 2004;161:473–9.CrossRefPubMed
19.
Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241–7.CrossRefPubMed
20.
Malla AK, Norman RM, Manchanda R, McLean TS, Harricharan R, Cortese L, et al. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatr Serv. 2002;53:458–63.CrossRefPubMed
21.
Malla A, Norman R, Manchanda R, Townsend L. Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. Psychol Med. 2002;32:1109–19.CrossRefPubMed
22.
Malla AK, Norman RM, McLean TS, McIntosh E. Impact of phase‐specific treatment of first episode of psychosis on Wisconsin Quality of Life Index (client version). Acta Psychiatr Scand. 2001;103:355–61.CrossRefPubMed
23.
McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull. 1996;22:305.CrossRefPubMed
24.
Nordentoft M, Jeppesen P, Abel M, Kassow P, Petersen L, Thorup A, et al. OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis One-year follow-up of a randomised controlled trial. Br J Psychiatry. 2002;181:s98–s106.CrossRef
25.
Grawe R, Falloon I, Widen J, Skogvoll E. Two years of continued early treatment for recent‐onset schizophrenia: a randomised controlled study. Acta Psychiatr Scand. 2006;114:328–36.CrossRefPubMed
26.
Petersen L, Jeppesen P, Thorup A, Abel M-B, Øhlenschlæger J, Christensen TØ, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ. 2005;331:602.CrossRefPubMedPubMedCentral
27.
Craig TK, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrojo M, et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ. 2004;329:1067.CrossRefPubMedPubMedCentral
28.
Garety PA, Craig TK, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman N, et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction Randomised controlled trial. Br J Psychiatry. 2006;188:37–45.CrossRefPubMed
29.
Harvey P, Lepage M, Malla A. Benefits of enriched intervention compared with standard care for patients with recent-onset psychosis: a metaanalytic approach. Can J Psychiatry. 2007;52:464.PubMed
30.
Linszen D, Dingemans P, Lenior M. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophr Res. 2001;51:55–61.CrossRefPubMed
31.
Bertelsen M, Jeppesen P, Petersen L, Thorup A, Øhlenschlæger J, Le Quach P, et al. Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch Gen Psychiatry. 2008;65:762–71.CrossRefPubMed
32.
Norman RM, Manchanda R, Malla AK, Windell D, Harricharan R, Northcott S. Symptom and functional outcomes for a 5 year early intervention program for psychoses. Schizophr Res. 2011;129:111–5.CrossRefPubMed
33.
Stout RL, Wirtz PW, Carbonari JP, Del Boca FK. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol Drugs. 1994;12:70–6.
34.
Birchwood M, Spencer E, McGovern D. Schizophrenia: early warning signs. Adv Psychiatr Treat. 2000;6:93–101.CrossRef
35.
36.
McFarlane WR, Lukens E, Link B, Dushay R, Deakins SA, Newmark M, et al. Multiple-family groups and psychoeducation in the treatment of schizophrenia. Arch Gen Psychiatry. 1995;52:679–87.CrossRefPubMed
37.
Zimmermann G, Favrod J, Trieu V, Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophr Res. 2005;77:1–9.CrossRefPubMed
38.
Turkington D, Dudley R, Warman DM, Beck AT. Cognitive-behavioral therapy for schizophrenia: a review. J Psychiatr Pract. 2004;10:5–16.CrossRefPubMed
39.
Miller WR. Motivational interviewing with problem drinkers. Behav Psychother. 1983;11:147–72.CrossRef
40.
Sobell LC, Sobell MB. Timeline follow-back. In: Measuring alcohol consumption. Totowa, NJ: Springer; 1992. p. 41–72.CrossRef
41.
Andreasen NC. Scale for the assessment of positive symptoms. Iowa City: University of Iowa; 1984.
42.
Andreasen NC. Scale for the assessment of negative symptoms. Iowa City: University of Iowa; 1983.
43.
Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261.CrossRefPubMed
44.
Ventura J, Green MF, Shaner A, Liberman RP. Training and quality assurance with the Brief Psychiatric Rating Scale:" the drift busters.". Int J Meth Psychiatr Res. 1993;3:221–44.
45.
Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766–71.CrossRefPubMed
46.
Morosini P, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning. Acta Psychiatr Scand. 2000;101:323–9.PubMed
47.
Chisholm D, Knapp MR, Knudsen HC, Amaddeo F, Gaite L, Van Wijngaarden B. Client Socio-Demographic and Service Receipt Inventory-European Version: development of an instrument for international research EPSILON Study 5. Br J Psychiatry. 2000;177:s28–33.CrossRef
48.
49.
Park LC, Lipman RS. A comparison of patient dosage deviation reports with pill counts. Psychopharmacologia. 1964;6:299–302.CrossRefPubMed
50.
Cassidy CM, Rabinovitch M, Schmitz N, Joober R, Malla A. A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. J Clin Psychopharmacol. 2010;30:64–7.CrossRefPubMed
51.
McGovern MP, Morrison DH. The chemical use, abuse, and dependence scale (CUAD): Rationale, reliability, and validity. J Subst Abuse Treat. 1992;9:27–38.CrossRefPubMed
52.
Horvath AO, Greenberg LS. Development and validation of the Working Alliance Inventory. J Couns Psychol. 1989;36:223.CrossRef
53.
Becker M, Diamond R, Sainfort F. A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Qual Life Res. 1993;2:239–51.CrossRefPubMed
54.
Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Res. 1992;6:209–23.CrossRefPubMed
55.
Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatr. 2005;162:441–9.CrossRefPubMed
56.
Cassidy CM, Norman R, Manchanda R, Schmitz N, Malla A. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr Bull. 2010;36:1001–8.CrossRefPubMed
57.
Jordan G, Lutgens D, Joober R, Lepage M, Iyer SN, Malla A. The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry. 2014;75:e566–72.CrossRefPubMed
58.
Buchanan RW, Carpenter WT. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis. 1994;182:193–204.CrossRefPubMed
59.
Malla A, Norman R, Bechard-Evans L, Schmitz N, Manchanda R, Cassidy C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol Med. 2008;38:1585–93.CrossRefPubMed
60.
Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8:470.CrossRefPubMed
61.
Melau M, Jeppesen P, Thorup A, Bertelsen M, Petersen L, Gluud C, et al. The effect of five years versus two years of specialised assertive intervention for first episode psychosis-OPUS II: study protocol for a randomized controlled trial. Trials. 2011;12:72.CrossRefPubMedPubMedCentral
Metadata
Title
A five-year randomized parallel and blinded clinical trial of an extended specialized early intervention vs. regular care in the early phase of psychotic disorders: study protocol
Authors
Danyael Lutgens
Srividya Iyer
Ridha Joober
Thomas G Brown
Ross Norman
Eric Latimer
Norbert Schmitz
Amal Abdel Baki
Sherezad Abadi
Ashok Malla
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2015
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-015-0404-2

Other articles of this Issue 1/2015

BMC Psychiatry 1/2015 Go to the issue

Research article

Social influences on seeking help from mental health services, in-person and online, during adolescence and young adulthood

Research article

The two-year course of late-life depression; results from the Netherlands study of depression in older persons

Study protocol

Expanding care for perinatal women with depression (EXPONATE): study protocol for a randomized controlled trial of an intervention package for perinatal depression in primary care

Research article

Continued cannabis use at one year follow up is associated with elevated mood and lower global functioning in bipolar I disorder

Research article

Elevated mitochondrial DNA copy number in peripheral blood cells is associated with childhood autism

Research article

Assessment and treatment of asylum seekers after a suicide attempt: a comparative study of people registered at mental health services in a Swedish location